Mytesi is well tolerated, with a low incidence of adverse events
The ADVENT clinical trial reported a low rate of adverse events, compared to placebo.
![Mask Group 63](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-63.png)
![Mask Group 63](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-63.png)
![Mask Group 39](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-39.png)
The most common adverse reactions occurring at a rate greater than placebo were2:
![Mask Group 58](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-58.png)
![Mask Group 59](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-59.png)
![Mask Group 60](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-60.png)
![Mask Group 61](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-61.png)
![Mask Group 62](https://hcp.mytesi.com/wp-content/uploads/Mask-Group-62.png)
References:
1. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals. 2018. 2. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of Crofelemer for non-infectious diarrhea in HIV-seropositive individuals (ADVENT Trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261-273.